The Effect of Glucagon-Like Peptide-1 (GLP-1) on Pulmonary Vascular Resistance (PVR) in Patients With Heart Failure
Information source: Papworth Hospital NHS Foundation Trust
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Heart Failure
Intervention: Glucagon-Like Peptide 1 (Drug)
Phase: Phase 1
Status: Not yet recruiting
Sponsored by: Papworth Hospital NHS Foundation Trust Overall contact:
Jayan Parameshwar, Phone: 01480 830541
Summary
This study aims to assess the effect of glucagon-like peptide-1 on cardiac output and
transpulmonary gradient in patients undergoing right heart catheterisation for clinical
reasons.
Clinical Details
Official title: The Effect of Glucagon-Like Peptide-1 (GLP-1) on Pulmonary Vascular Resistance (PVR) in Patients With Heart Failure
Study design: Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science
Primary outcome: Change in Pulmonary Vascular Resistance with Glucagon-Like Peptide-1
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Age over 18
- Able to give informed consent
- On the waiting list for heart transplant
- Left Ventricular Dysfunction awaiting catheterisation
Exclusion Criteria:
- Nicorandil, glibenclamide, Dipeptidyl Peptidase-4 inhibitor, Glucagon-Like Peptide-1
receptor agonist or insulin
- Women of child bearing age and breast feeding women
- Cardiac pacemaker or other implanted metallic device
- Unable to give informed consent
Locations and Contacts
Jayan Parameshwar, Phone: 01480 830541
Papworth Hospital NHS Foundation Trust, Papworth Everard CB23 3RE, United Kingdom; Not yet recruiting
Parameshwar, Phone: 01480 830541
Additional Information
Starting date: June 2014
Last updated: May 1, 2014
|
